Myriad Genetics to Present at the JPMorgan Healthcare Conference on January 8, 2007

SALT LAKE CITY, January 2, 2007—Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that its
President and CEO, Peter Meldrum, is scheduled to present an overview
of the Company at the 25th Annual JPMorgan Healthcare Conference, at
8:00 am Pacific Time on January 8, 2007, at the Westin St. Francis
Hotel in San Francisco.

A live audio webcast of this presentation will be available online
and can be accessed through a link on Myriad's home page at
www.myriad.com. The presentation will also be recorded for replay,
and can be accessed under the Investor Relations heading of Myriad's
web site, beginning several hours after the live presentation.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of novel healthcare products. The Company develops and
markets molecular
diagnostic products, and is developing and intends
to market therapeutic products, including Flurizan, our lead
candidate for the treatment of Alzheimer's disease. Myriad's news and
other information are available on the Company's Web site at
www.myriad.com.

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on management's current
expectation and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those set forth
or implied by forward-looking statements. These include, but are not
limited to, uncertainties as to the extent of future government
regulation of Myriad Genetics' business; uncertainties as to whether
Myriad Genetics and its collaborators will be successful in
developing, and obtaining regulatory approval for, and commercial
acceptance of, therapeutic compounds; the risk that markets will not
exist for therapeutic compounds that Myriad Genetics develops or if
such markets exist, that Myriad Genetics will not be able to sell
compounds, which it develops, at acceptable prices; and the risk that
the Company will not be able to sustain revenue growth for its
predictive medicine business and products. These and other risks are
identified in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K for
the fiscal year ended June 30, 2006. All information in this press
release is as of January 2, 2007, and Myriad undertakes no duty to
update this information unless required by law.